Research progress of SHP-1 agonists as a strategy for tumor therapy
Molecular Diversity · 2025-10 · 29 (5) · 4953-4961
DOI: 10.1007/s11030-024-11059-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Diversity, online erschienen am 30.12.2024. Verfasst von Xiaoyue Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Science, China Pharmaceutical University, Nanjing, 211198, People's Republic of China. Hauptthemen laut MEDLINE: Protein Tyrosine Phosphatase, Non-Receptor Type 6, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, China Postdoctoral Science Foundation, Qinglan Project of Jiangsu Province of China.
Abstract (Originalsprache)
Src homology-2 domain-containing protein tyrosine phosphatase 1 (SHP-1) is a member of protein tyrosine phosphatase (PTP) family, and serves as a crucial negative regulator of various oncogenic signaling pathways. The development of SHP-1 agonists has garnered extensive research attention and is considered as a promising strategy for treating tumors. In this review, we comprehensively analyze the advancements of SHP-1 agonists, focusing on their structures and biological activities. Based on the structure skeletons, we classify these SHP-1 agonists as kinase inhibitors, sorafenib derivatives, obatoclax derivatives, lithocholic acid derivatives and thieno[2,3-b]quinoline derivatives. Additionally, we discuss the potential opportunities and challenges for developing SHP-1 agonists. It is hoped that this review will provide inspiring insights into the discovery of drugs targeting SHP-1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Science, China Pharmaceutical University, Nanjing, 211198, People's Republic of China.
- Academy of Chinese Medicine Sciences, Henan University of Chinese Medicine, Zhengzhou, 450046, Henan, China.
- School of Science, China Pharmaceutical University, Nanjing, 211198, People's Republic of China. chenyadong@gmail.com.
- School of Science, China Pharmaceutical University, Nanjing, 211198, People's Republic of China. lu_shuai@cpu.edu.cn.
- Shenzhen Key Laboratory of Viral Oncology, Ministry of Science and Innovation, ShenZhen Hospital, Southern Medical University, Shenzhen, 518000, People's Republic of China. wzj95cpu@163.com.
Förderung
- Natural Science Foundation of Jiangsu Province
- China Postdoctoral Science Foundation
- Qinglan Project of Jiangsu Province of China
Zitieren
APA
Liu, X., He, Q., Sun, S., Lu, X., Chen, Y., Lu, S., & Wang, Z. (2025). Research progress of SHP-1 agonists as a strategy for tumor therapy. Molecular Diversity, 29(5), 4953-4961. https://doi.org/10.1007/s11030-024-11059-5
Vancouver
Liu X, He Q, Sun S, Lu X, Chen Y, Lu S, et al. Research progress of SHP-1 agonists as a strategy for tumor therapy. Molecular Diversity. 2025;29(5):4953-4961. doi:10.1007/s11030-024-11059-5
BibTeX
@article{Liu2025,
author = {Liu, Xiaoyue and He, Qindi and Sun, Shuding and Lu, Xun and Chen, Yadong and Lu, Shuai and Wang, Zhijie},
title = {Research progress of SHP-1 agonists as a strategy for tumor therapy},
journal = {Molecular Diversity},
year = {2025},
volume = {29},
number = {5},
pages = {4953--4961},
doi = {10.1007/s11030-024-11059-5}
}
EUVIMED